Demonstration of viral thymidine kinase inhibitor and its effect on deoxynucleotide metabolism in cells infected with herpes simplex virus. by Nutter, L M et al.
Vol. 31, No. 3ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1987, p. 368-374
0066-4804/87/030368-07$02.00/0
Copyright © 1987, American Society for Microbiology
Demonstration of Viral Thymidine Kinase Inhibitor and Its Effect on
Deoxynucleotide Metabolism in Cells Infected with
Herpes Simplex Virus
LOUISE M. NUTTER,' SUSAN P. GRILL,' GINGER E. DUTSCHMAN,' RAM A. SHARMA,2
MIROSLAV BOBEK,2 AND YUNG-CHI CHENGl*
Department ofPharmacology, School of Medicine, University ofNorth Carolina, Chapel Hill, North Carolina 27514,1
and Experimental Therapeutics, Roswell Park Memorial Institute, Buffalo, New York 142632
Received 28 August 1986/Accepted 4 November 1986
The thymidine analog 5'-ethynylthymidine was a potent inhibitor of herpes simplex virus type 1 (strain
K(S)-induced thymidine kinase with a Ki value of 0.09 ,uM. 5'-Ethynylthymidine was less inhibitory against
herpes simplex virus type 2 (strain 333)-induced thymidine kinase with a Ki of 0.38 ,uM and showed no
inhibition against human cytosolic thymidine kinase under the conditions tested. The compound was effective
against the altered thymidine kinase induced by acyclovir- and bromovinyldeoxyuridine-resistant virus
variants. At 100 FM 5'-ethynylthymidine, the cellular pool size ofdTTP in herpes simplex virus type 1-infected
cells was 5% that of infected cells receiving no drug treatment, while there was no significant effect on the pool
sizes of dATP, dGTP, and dCTP. There was a positive correlation between dTTP pools and the intracellular
thymidine kinase activity of herpes simplex virus type 1-infected cells. When tested alone, 5'-ethynylthymidine
exhibited no antiviral activity, but it antagonized the antiviral efficacy of five compounds which require viral
thymidine kinase for their action.
Herpes simplex viruses type 1 (HSV-1) and type 2
(HSV-2) and varicella-zoster virus induce unique virus-
specified thymidine kinases (dThd kinase) in infected cells
(2, 8, 18, 20). In the past, major efforts were made to develop
antiviral compounds that would serve as "selective alterna-
tive substrates" (3) for virus-specified dThd kinase. While
the activity of viral dThd kinase does not appear to be
critical for virus replication in cell culture systems (19),
studies have suggested that it is important for virus patho-
genicity and reactivation of latent virus from neural cells (9,
14, 30). In this report, we describe the effects of 5'-
ethynylthymidine (5'-Et-dThd) (Fig. 1) as a selective inhibi-
tor for HSV dThd kinase and its impact on deoxynucleotide
metabolism in virus-infected cells.
MATERIALS AND METHODS
Materials. All chemicals used were reagent grade or bet-
ter. 3H-labeled deoxynucleoside 5'-triphosphates (dNTPs)
were purchased from ICN Radiochemicals, Irvine, Calif.
dThd, dNTPs, and calf thymus DNA were purchased from
Sigma Chemical Co., St. Louis, Mo. DNA polymerase I
(endonuclease-free) and hydroxyurea were purchased from
Boehringer Mannheim Biochemicals, Indianapolis, Ind.
RPMI 1640 medium, fetal bovine serum, and kanamycin
were purchased from Hazleton Research Products, Inc.,
Denver, Pa. 5'-Et-dThd was synthesized by published pro-
cedures (29). Acyclovir (ACV) was a gift from Burroughs
Wellcome Co., Research Triangle Park, N.C., and 9-(1,3-
dihydroxy-2-propoxy-methyl)guanine (DHPG) was from
Syntex Co. 5'-Amino-dThd (5'-NH2-dThd) was provided by
William Prusoff, Yale University, New Haven, Conn.
Fluoroiodo-arabinosyl-cytosine (FIAC) and (E)-5-(2-
bromovinyl)-2'-deoxyuridine (BVDU) were gifts from J. J.
Fox (Sloan-Kettering Cancer Institute) and G. D. Searle &
Co., respectively.
* Corresponding author.
Cells. The cells used in this study were HeLa S3, HeLa
BU (dThd kinase deficient), Vero, and KB6B (13). The cells
were maintained at 37°C in RPMI 1640 medium supple-
mented with 5% fetal bovine serum and 100 p.g of kanamycin
per ml. All cultures were found to be mycoplasma-free by
the Bethesda Research Laboratories Mycotect (24) and
4,6-diamidino-2-phenylindole fluorescence (28) techniques.
Virus stocks. The viruses used in this study were HSV-1
(strains KOS, SC16, B3, and Tr7) and HSV-2 (strain 333).
The HSV SC16 parental strain and dThd kinase mutants B3
and Tr7, which were isolated in the presence of BVDU at 10
,ug/ml and ACV at 1 ,ug/ml, respectively (9, 15), were gifts
from G. Darby and H. Field (Cambridge University,
Cambridge, United Kingdom). HSV-1 or HSV-2 was added
at a low multiplicity of infection (0.01 PFU per cell) to
confluent Vero monolayers. After a 1-h adsorption period,
30 ml of RPMI 1640 supplemented with 2% fetal bovine
serum was added. The cells were then incubated at 37°C for
24 h followed by incubation at 34°C for 48 h (HSV-1) or 24 h
(HSV-2). At the end of the incubation period the cells were
suspended and frozen at -70°C. Before use the virus stocks
were sonicated with two 10-s bursts on a Branson Sonifier
with a cup horn adapter to retain sterility. The suspension
was centrifuged for 10 min at 1,200 x g to remove the
remaining cells. The medium containing virus was then
aliquoted into sterile tubes and stored at -70°C.
Cell and virus growth inhibition. Cell growth inhibition and
the virus yield assay were performed as previously described
(4) with the exceptions that all studies were done with 5%
dialyzed fetal bovine serum; the multiplicity of infection was
3 PFU per cell, and Vero cells were used instead of CV-1
cells for titration in the virus yield assays.
dNTP pool assay. dNTP pool measurements were done as
previously described (31). 5'-Et-dThd alone had no effect on
the dNTP pool assay.
Enzyme purification, enzyme assays, IC50, and Ki determi-
nations. The cellular cytosolic dThd kinase used in studies to
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FIG. 1. Structure of 5'-Et-dThd.
determine the Ki values was isolated from KB6B cells. The
HSV-1 and HSV-2 dThd kinases were extracted from dThd
kinase-deficient HeLa BU cells infected with HSV-1 (strain
KOS) and HSV-2 (strain 333), respectively. All these dThd
kinases were purified by affinity column chromatography
procedures as described previously (22). The dThd kinase
assay was the same as that described previously (5). Incu-
bations were conducted at 37°C for 60 min, and the Ki and
inhibitor concentration for 50% inhibition of enzyme activity
(IC50) values were determined as described previously (6).
The thymidylate kinase and synthase assays were per-
formed as described previously (7, 12, 27). dThd phosphor-
ylase activity was determined by monitoring conversion of
[14C]dThd to [14C]thymine by high-performance liquid chro-
matography. Briefly, after a 30-min incubation of enzyme
extract with radiolabeled dThd at 37°C, the reaction was
stopped by the addition of 25% trichloroacetic acid. After
neutralization and centrifugation, the supernatants were
loaded onto an Alltech Lichrosorb RP-18 column, and the
column was eluted at a rate of 1 ml/min with 5 mM KH2PO4
(pH 3.5)-10% methanol. Fractions of 1 ml were collected,
and radioactivity associated with dThd and thymine (as
previously determined by retention times of authentic mark-
ers measured by their A265) was measured by scintillation
counting. For evaluation of whether 5'-Et-dThd could serve
as a substrate for dThd phosphorylase, reactions were done
as described above, except that 5'-Et-dThd was used instead
of [14C]dThd; metabolites were then analyzed by high-
performance liquid chromatography as described above.
Intracellular dThd kinase activity. HeLa S3 or HeLa BU
cells (1.5 X 106/ml) were mock infected or infected with
HSV-1 or HSV-2 at 3 PFU per cell and incubated at 37°C for
a 1-h adsorption period. The medium was then removed, and
the cells were washed with growth medium and resuspended
at a cell density of 5 x 105/ml in RPMI 1640 medium
supplemented with kanamycin (100 ,ug/ml) and 5% dialyzed
fetal bovine serum. At 9 h post-HSV infection, [14C]dThd
(0.16 ,uCi/ml; 1 ,uM dThd) and different amounts of 5'-Et-
dThd were added to the medium depending on experimental
conditions. At the end of the labeling period (1 h), the cells
were pelleted by centrifugation, washed with phosphate-
buffered-saline, and resuspended in a small volume of phos-
phate-buffered saline. Samples were then pipetted directly
onto DE81 disks which were immediately washed in 100%
ethanol. The DE81 disks were washed two additional times
in 100% ethanol, and then radioactivity associated with them
was measured by scintillation counting in 5 ml of aqueous
counting fluid. In this manner, total intracellular dThd kinase
activity was determined from the sum of radioactive dThd
nucleotides plus the dTMP associated with DNA both pre-
cipitated directly on the DE81 disks.
RESULTS
Activity of 5'-Et-dThd against viral and cellular dThd
kinase activities in vitro and in cell culture. HSV-1- and
HSV-2-induced dThd kinases that are different from those of
their host cellular counterparts (2) were examined for their
sensitivity to 5'-Et-dThd. The activity of 5'-Et-dThd against
purified HSV-1 (KOS), HSV-2 (333), and human cytosolic
dThd kinases at a concentration of 100 ,uM ['4C]dThd in the
assay mixture is shown in Fig. 2A. At 10 ,uM, 5'-Et-dThd
inhibited 50 and 25%, respectively, of HSV-1 and HSV-2
dThd kinase activities. Furthermore, 5'-Et-dThd was a po-
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FIG. 2. Effect of 5'-Et-dThd on in vitro dThd kinase activity and
intracellular dThd phosphorylation. (A) Affinity column-purified
human cytosolic (l), HSV-1 (KOS) (A), and HSV-2 (333) (0) dThd
kinases were examined for their sensitivity to 5'-Et-dThd as de-
scribed in Materials and Methods. The 100% dThd kinase activity
values for human cytosolic, HSV-1, and HSV-2 enzymes were 9.4 x
10-3, 23 x 10-3, and 21 x 10-3 units of enzyme, respectively. (B)
The effect of 5'-Et-dThd on intracellular dThd phosphorylation was
measured in HSV-1 (KOS) (A)-, HSV-2 (333) (0)-, or mock (E)-
infected cells. HeLa BU cells were the host cells for HSV-1 and
HSV-2 9-h infections, and HeLa S3 was the host for the mock
infection. The 100% dThd phosphorylation values for HeLa BU
cells infected with HSV-1 and HSV-2 and mock-infected HeLa S3
cells were 33,000, 20,000 and 10,667 cpm/106 cells, respectively. For
details see the text.
VOL. 31, 1987 369
ANTIMICROB. AGENTS CHEMOTHER.
dTMP kinase activity with IC50 values of 0.3 and 0.8 p.M,
respectively, when dTMP substrate concentrations of 25 and
100 ,uM were used in the assay (Table 1). No demonstrable
effects on purified human cytosolic dThd kinase were ob-
served when concentrations of 5'-Et-dThd as high as 150 p.M
were used under identical assay conditions (Fig. 2A). Re-
sults from kinetic studies showed that 5'-Et-dThd was a
competitive inhibitor with respect to dThd, and Ki values
were estimated to be 0.09 ± 0.02 and 0.38 ± 0.18 ,uM for
HSV-1 (strain KOS) and HSV-2 (strain 333) dThd kinase,
respectively (Table 1). 5'-Et-dThd did not serve as a sub-
strate for viral dThd kinase as determined by the phosphate
transfer assay with dThd kinase from HSV-1 (KOS)-infected
HeLa BU cells as an enzyme source and 2 mM ATP (11).
The effects of 5'-Et-dThd on intracellular dThd kinase
activities of HSV-1- and HSV-2-infected HeLa BU cells and
on mock-infected HeLa S3 cells at 9 h postinfection were
examined (Fig. 2B). At 100 ,uM, 5'-Et-dThd inhibited 97% of
HSV-1 dThd kinase-mediated ["4C]dThd phosphorylation,
but only 50% of that mediated by HSV-2 dThd kinase in
HSV-2-infected HeLa BU cells. Thus, differences in the
potency of 5'-Et-dThd against HSV-1- and HSV-2-induced
dThd kinases in vitro and in cell culture are clearly demon-
strated. The accumulation of intracellular phosphorylated
[14C]dThd metabolites was increased slightly in mock-
infected HeLa S3 cells treated with increasing amounts of
5'-Et-dThd (Fig. 2B).
The role of host dThd kinase in virus-infected cells was
explored by comparing the effect of 5'-Et-dThd (25 ,uM) on
intracellular dThd phosphorylation in HeLa S3 and HeLa
BU cells at 9 h postinfection by the procedures described
above. After a 1-h labeling period in the presence of drug,
12.5 and 80% of the untreated control dThd-phosphorylating
activities were present in HeLa BU cells infected with
HSV-1 and HSV-2, respectively (Fig. 3A and B). When
HeLa S3 cells were used as the host cells for infection, these
values were increased to 25 and 88%, respectively (Fig. 3C
and D). Thus, the host dThd kinase activity in virus-infected
cells was still functional at 9 h postinfection.
Activity of 5'-Et-dThd against dThd kinase activities in-
TABLE 1. Effect of 5'-Et-dThd on viral dThd kinase, viral dThd
kinase-associated dTMP kinase, and host dTMP kinase activitiesa
IC50 of
IC50 of dThd virus-associated
Virus type kinase (jLM) dTMP kinase
and strain Kb (>M)
Intra- i ird2 Lelo~M
cellularIc 25 F±M 100 jiM'
HSV-1




HSV-2 (333) 100 46 0.38 ± 0.18 (23) 60.0f
a All studies were performed with HeLa BU cells.
b Ki determinations were performed with affinity column-purified dThd
kinase; numbers in parentheses reflect number of determinations for Ki ±
standard deviation.
c Intracellular [14C]dThd phosphorylation.
d IC50 determinations were performed with enzyme extracts of cells in-
fected with designated virus; dThd concentration was 100 jiM in the assay.
e dTMP substrate concentrations used in assay; crude extracts were used
for the assay.





















FIG. 3. Role of host dThd kinase in HSV-1 (KOS)- and HSV-2
(333)-infected cells. Intracellular dThd phosphorylation was evalu-
ated in HeLa BU cells infected for 9 h with HSV-1 (A) or HSV-2 (B)
and in HeLa S3 cells infected with HSV-1 (C) or HSV-2 (D) in the
absence (0) or presence (0) of 25 ,uM 5'-Et-dThd. For details, see
the text.
duced by different types and strains of HSV. Virus mutants
which induce viral dThd kinases that exhibit altered sub-
strate specificities (dThd kinaseA) and are resistant to selec-
tive antiviral agents have been isolated (21). The effect of
5'-Et-dThd on the in vitro and intracellular dThd kinase
activities of two such dThd kinase variants, Tr7 and B3
(ACV and BVDU resistant, respectively) was examined,
together with their parental HSV-1 strain (SC16). The results
are shown in Table 1. The dThd kinase activities of these
dThd kinase mutants, whose induced dThd kinase levels are
similar to those of the parent SC16 strain (21), were sensitive
to 5'-Et-dThd, with IC50 values of less than 10 ,uM both in
vitro and in cell culture.
Interaction of 5'-Et-dThd with other dThd-metabolizing
enzymes. The effect of 5'-Et-dThd against human dTMP
synthase was examined. At 100 ,uM 5'-Et-dThd, no effect on
dTMP synthase from HSV-1-infected HeLa BU cells was
observed when 25 ,uM dUMP substrate and 150 ,uM 5,10-
methylene-tetrahydrofolate were used in the enzyme assay.
Furthermore, 5'-Et-dThd was neither a substrate nor an
inhibitor of dThd phosphorylase. Specifically, no thymine
product was detected with 735 ,uM 5'-Et-dThd substrate with
0.26 or 21.5 U of dThd phosphorylase from HSV-1 (strain
KOS)-infected cells or human liver, respectively. Similarly,
150 ,uM 5'-Et-dThd did not inhibit the phosphorylase reac-
tion with 600 ,uM dThd as the substrate for the same units of
activity described above. In terms of the interaction of
5'-Et-dThd with purified human chronic lymphocytic leuke-
mia dTMP kinase, the IC50 was 37.5 ,uM when 25 ,uM dTMP
was used in the enzyme assay (data not shown).
Effect of 5'-Et-dThd on dNTP pools in HSV-1-infected cells.
In view of the potent inhibition of 5'-Et-dThd on HSV-1
dThd kinase and its associated dTMP kinase, we examined
370 NUTTER ET AL.
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FIG. 4. Effect of 5'-Et-dThd on dNTP pools in HSV-1-infected
cells. (A) dTTP pools were measured in acid-soluble extracts from
HSV-1-infected HeLa BU cells (0, 0) and HSV-1-infected HeLa S3
cells (A, A) in the absence (solid symbols) or presence (open
symbols) of 100 ,uM 5'-Et-dThd. (B) The effect of 5'-Et-dThd on
dCTP (0), dGTP (A), dATP (x), and dTTP (0) pools in HeLa BU
cells infected for 9 h with HSV-1 (KOS) and on dTTP pools in HeLa
BU cells infected with a dThd kinase-dTMP kinase-deficient HSV-1
strain (MDK) (O) was examined. The 100% values for dCTP, dGTP,
dATP, and dTTP pools in HSV-1 (KOS)-infected HeLa BU cells
were 64, 65, 75, and 159 ,uM, respectively, and the dTTP pool of
MDK-infected HeLa BU cells was 70 ,uM.
the effect of 5'-Et-dThd on dNTP pools in HSV-1-infected
cells. At 12 h postinfection, the dTTP pool of HeLa BU cells
treated with 100 ,uM 5'-Et-dThd was reduced by 95% as
compared with that of untreated infection control cells (Fig.
4A). When HeLa S3 cells were used as the host cell for
infection, the dTTP pool was reduced by 80% as compared
with that of untreated infected control cells (Fig. 4A). This
difference could be related to the activity of host dThd
kinase in HeLa S3 cells. When other dNTP pools in the
virus-infected cells were examined, no significant effect of
5'-Et-dThd on dATP, dCTP, and dGTP pools in 9-h HSV-1
(KOS)-infected HeLa BU cells was observed (Fig. 4B).
Thus, the possibility that ribonucleotide reductase is inhib-
ited by 5'-Et-dThd is not likely.
The decrease of dTTP pools in virus-infected cells caused
by 5'-Et-dThd could be due to inhibition of viral dThd kinase
or its intrinsic dTMP kinase. To explore whether inhibition
of this intrinsic dTMP kinase activity (which constitutes 10%
of the total dTMP kinase activity in 9-h-infected cells) is
sufficient to explain these results, we examined the impact of
5'-Et-dThd on dTTP pools of HSV-1 (strain MDK)-infected
HeLa BU cells; the MDK strain of HSV-1 is unable to
induce viral dThd kinase or its intrinsic dTMP kinase. At 100
jxM 5'-Et-dThd, there was only 45% inhibition ofdTTP pools
(Fig. 4B). This suggested that the activity of host dTMP
kinase in infected cells, even though partly inhibited by
5'-Et-dThd, is sufficient enough to maintain partially the
dTTP pool, and the inhibition of the viral dThd kinase-
associated dTMP kinase is not a major factor in decreasing
dTTP pools in 5'-Et-dThd-treated cells.
Correlation of viral dThd kinase inhibition and dTTP pools.
The impact of viral dThd kinase inhibition on dTTP pools in
infected cells is demonstrated in Fig. 4 and suggests that
viral dThd kinase activity is important for maintenance of
this pool. We investigated this further by examining the
correlation of viral dThd kinase activity with dTTP pool
levels in HSV-1 (strain KOS)-infected cells (Fig. 5). In this
study, dThd kinase activity and dTTP pool levels were
measured at 9 h postinfection of HeLa S3 or HeLa BU cells
with HSV-1 (strain KOS) in the presence of different con-
centrations of 5'-Et-dThd. When the results were plotted, a
positive correlation was found between dThd kinase activity
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FIG. 5. Correlation of intracellular dThd kinase activity with
dTTP pools. Intracellular dThd kinase activity and dTTP pools were
measured in HeLa S3 (A) and HeLa BU (0) cells infected with
HSV-1 (KOS) for 9 h in the presence of different concentrations of
5'-Et-dThd. The contribution of host dThd kinase activity (15%) was
subtracted from total dThd kinase activity, and the resulting values
were plotted versus the dTTP pool (A). All values are depicted as
the percentage of the control dThd kinase activity and dTTP pool
measurements in the absence of 5'-Et-dThd (100%). The concentra-
tions of 5'-Et-dThd used for studies with HSV-1-infected HeLa S3
cells were 0, 2.5, 25, and 100 ,uM, and those for HSV-1-infected
HeLa BU cells were 0, 2, 10, and 100 ,uM. The 100% values for the
dTTP pools in HSV-1-infected HeLa S3 and HeLa BU cells were 56
and 40 ,uM, respectively. The 100%o intracellular dThd kinase
activity values for HSV-1- and HSV-2-infected HeLa BU cells were
90,000 and 50,000 cpm/106 cells, respectively.
B , I I




kinase activity contributed by HeLa S3 cells was subtracted
from the total dThd kinase activity and replotted against the
dTTP level, the result was superimposable on that obtained
from dThd kinase-deficient infected cells (Fig. 5). These
results suggest that viral dThd kinase activity is of major
importance in dTTP pool maintenance in HSV-1-infected
cells. The presence of a significant dTTP pool in the dThd
kinase strain (MDK) of HSV-1-infected cells (Fig. 4) was not
taken into consideration for this conclusion since this strain
could have more than one mutation in addition to not being
able to induce viral dThd kinase in infected cells.
Effects of 5'-Et-dThd on antiviral activity of several agents.
By itself, 5'-Et-dThd had no effect on virus yield (Table 2)
and on virus DNA synthesis as determined from isopycnic
centrifugation studies in which 32PO4-labeled virus DNA was
separated from host DNA (L. M. Nutter, S. P. Grill, and
Y.-C. Cheng, unpublished observation). Nucleoside analogs
have been developed based on the "selective alternate
substrate" strategy (3) and depend on viral dThd kinase for
their antiviral activity. We examined the effect of 5'-Et-dThd
on the antiviral efficacy of five such analogs, ACV, DHPG,
FIAC, BVDU, and 5'-NH2-dThd. The effect of 5'-Et-dThd
on the activity of the five agents was determined by the virus
yield assay with HSV-1 (strain KOS)-infected HeLa BU
cells. At 100 ,uM, 5'-Et-dThd reversed the antiviral activity
of ACV (15 ,uM),' DHPG (2 ,uM), FIAC (1 ,LM), BVDU (1
,uM), and 5'-NH2-dThd (500 1xM) 35-, 100-, 98-, 15-, and
250-fold, respectively (Table 2). Results from the present
study suggest that viral dThd kinase is important for dTTP
pool maintenance in infected cells (Fig. 4 and 5). Therefore,
we evaluated the combined effects of inhibition of viral dThd
kinase and ribonucleotide reductase activities on virus rep-
lication. The results of this study are depicted in Table 2 and
show that there was no significant effect of 5'-Et-dThd on the
antiviral activity of hydroxyurea.
DISCUSSION
We demonstrated that 5'-Et-dThd is a selective inhibitor
of HSV-induced dThd kinase and has no effect on human
cytosolic dThd kinase. 5'-Et-dThd is more potent against
HSV-1 than HSV-2 dThd kinase in vitro and in cell culture.
The differential activity of 5'-Et-dThd against type 1 and
type 2 dThd kinases appears to be due to a decreased affinity
of the compound for type 2 dThd kinase as reflected by their
Ki values (HSV-1 Ki, 0.09 ,uM; and HSV-2 Ki, 0.38 ,uM;
Table 1).
It is possible that some metabolism of 5'-Et-dThd occurs
inside cells. The increase of dThd phosphorylation in
uninfected cells treated with 5'-Et-dThd (Fig. 2) may be due
to the catabolism of 5'-Et-dThd by degradative enzymes
(e.g., dThd phosphorylase). In this manner, 5'-Et-dThd
could protect dThd nucleotides from these degradative ac-
tivities. Alternatively, it cannot be ruled out that a decreased
efflux of dThd from uninfected cells occurred in the presence
of 5'-Et-dThd. Our results suggest that 5'-Et-dThd is not
metabolized by dThd phosphorylase. However, possible
effects of this compound on dThd nucleotide efflux or
intracellular phosphatases were not ruled out. 5'-Et-dThd
could not be phosphorylated by viral dThd kinase. Thus,
possible mutagenic effects caused by metabolism and subse-
quent incorporation of 5'-Et-dThd into cellular DNA are not
anticipated. Furthermore, 5'-Et-dThd (100 ,uM) had no effect
on host (HeLa BU) DNA synthesis as measured by 32P04
incorporation studies, nor did it inhibit HeLa BU or HeLa
S3 cell growth.
TABLE 2. Effect of 5'-Et-dThd on activity of antiviral agentsa
% PFU with a 5'-Et-dThd concn (,uM) of:
Drug (,uM)
0 2.5 25 100
None 100 97 96 99
ACV (15) 2 9 45 70
FIAC (1) 0.6 26 59
DHPG (2) 0.1 0.2 4 10
BVDU (1) 0.9 9.5 13
5'-NH2-dThd (500) 0.2 0.3 3 50
Hydroxyurea (1 mM) 15 19 14 10
a The antiviral activities of several agents in the presence and absence of
5'-Et-dThd were determined by the virus yield assay with HSV-1 (KOS)-
infected cells.
The amount of phosphorylated dThd nucleotides in HSV-
1-infected HeLa S3 cells was higher than that in HeLa BU
cells, owing to the fact that host and viral dThd kinase can
utilize dThd as a substrate. The dThd phosphorylation in
virus-harboring, resting-nondividing cells with diminished
host dThd kinase activities would, therefore, have increased
susceptibility to 5'-Et-dThd relative to that in a dividing cell.
Thus, utility for such a compound against the viral dThd
kinase activity in a neural cell can be envisaged, which could
be critical for the viral reactivation process.
Virus variants which induce dThd kinase activities with
altered substrate specificities (dThd kinaseA) and are resis-
tant to antiviral agents such as ACV have been isolated in
the laboratory (21) and, recently, from clinic samples (23,
25). We examined whether 5'-Et-dThd could inhibit the
dThd kinase induced by the virus variants Tr7 and B3 (ACV
and BVDU resistant, respectively) and found that 5'-Et-
dThd was an efficient inhibitor of these dThd kinaseA activ-
ities in vitro and in cell culture (Table 1). Thus, a potential
use of 5'-Et-dThd for inhibition of viral dThd kinase activity,
whether of a wild-type or altered substrate phenotype, is
suggested.
Treatment of HSV-1-infected HeLa BU cells with 5'-Et-
dThd (100 ,uM) resulted in a 95% decrease of the dTTP pool,
whereas dCTP, dATP, and dGTP pools were not signifi-
cantly altered (Fig. 4). The effect of 5'-Et-dThd on dTTP
pool levels was more pronounced in HeLa BU than in HeLa
S3 cells which is consistent with the pattern observed for
intracellular dThd phosphorylation (Fig. 3), suggesting a role
of host dThd kinase in dThd phosphorylation in virus-
infected cells. When the relationship of intracellular dThd
kinase activity and dTTP pools of infected cells was exam-
ined, a good correlation was found (Fig. 5). The differences
in dTTP pool levels of HeLa S3 and HeLa BU cells were
correlated with their dThd kinase activities. Since no effects
of 5'-Et-dThd were found on the de novo synthesis of dTTP
(i.e., dTMP synthase and ribonucleotide reductase),
whereas significant inhibition of viral dThd kinase was
observed, it is suggested that viral dThd kinase plays a major
role in the maintenance ofdTTP pools in virus-infected cells.
Previously, we showed that approximately 30% of the dTTP
pool was derived from host DNA breakdown and that the
remainder was from de novo sources in HSV-2-infected cells
(26). A role for dThd kinase in the formation of dTTP
originating from host DNA breakdown was postulated. The
results of the present study with HSV-1 suggest that viral
dThd kinase, possessing dThd kinase and dTMP kinase
activities, is very important in dTTP pool regulation, regard-
less of the dTTP origin (e.g., de novo or host DNA break-
down). Viral dThd kinase but not its associated dTMP kinase
activity is most important in this dTTP pool maintenance.
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However, it is not known whether dThd nucleotide derived
from de novo synthesis and host DNA is excreted from the
cell and phosphorylated after reentry or whether thymidine
so derived is phosphorylated directly inside the cell, or both.
It should be pointed out that 5'-Et-dThd may have other
effects intracellularly, which could also result in decreased
dTTP pools (e.g., dTMP synthase, nucleotide phosphatase,
nucleoside diphosphate kinase). We do not favor such a
possibility. This is based on the following observations. We
did not observe any effects of 5'-Et-dThd on dTMP synthase
activity in vitro, and effects of this compound on
phosphatases and nucleoside diphosphate kinase activities
are unlikely since results from this study show that other
dNTP pools in HSV-1-infected cells were not significantly
affected by 5'-Et-dThd.
The remainder of the dTTP pool (approximately 5 FiM)
present in HSV-1-infected HeLa BU cells treated with 100
,uM 5'-Et-dThd could be derived from host dTMP kinase
activity. This level of dTTP is apparently able to sustain
HSV-1 DNA synthesis, with no adverse effects on virus
replication (Table 2). Thus, extensive depletion of dTTP
pools, below the dTTP Km for virus polymerase (ca. 0.45 F.M
[17]) is probably required before antiviral effects are seen.
Alone, 5'-Et-dThd exhibited no antiviral activity in HSV-
1-infected HeLa BU cells, which is in accordance with the
observation that viral dThd kinase is not critical for replica-
tion of HSV in cell culture systems. 5'-Et-dThd reversed the
antiviral efficacy of ACV, DHPG, FIAC, BVDU, and 5'-
NH2-dThd, all of which require viral dThd kinase for their
activity. It was anticipated that the diminished dTTP pools in
HSV-1-infected cells caused by 5'-Et-dThd would augment
the antiviral action of the phosphorylated forms of 5'-NH2-
dThd and BVDU, the latter which could compete with dTTP
for virus polymerase; this was not the case. Thus, apprecia-
ble levels of phosphorylated 5'-NH2-dThd or BVDU deriv-
atives apparently did not form in HSV-1-infected cells in the
presence of 5'-Et-dThd. The antiviral actions of FIAC and
the guanosine analogs ACV and DHPG, whose phosphor-
ylated derivatives compete against dCTP and dGTP, respec-
tively, for HSV polymerase (1, 10, 16), were reversed by
5'-Et-dThd. Since 5'-Et-dThd significantly decreases the
dTTP pools of infected cells, this compound could be very
beneficial in combination with viral dThd kinase-indepen-
dent agents that must compete with dTTP for virus polymer-
ase.
In summary, we showed that 5'-Et-dThd is a potent
inhibitor of HSV dThd kinase. Mutagenic effects of 5'-Et-
dThd owing to its incorporation into host DNA are not
anticipated, nor does 5'-Et-dThd have significant cytotoxic-
ity in uninfected human cells. A critical role for viral dThd
kinase in dTTP pool maintenance in virus-infected cells was
postulated.
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